|
|
 |
|
Viewing report
|
|
|
|
Urinary Tract Infections: Growing Resistance Rates bring Opportunities for Both New and Old Drugs
Datamonitor, April 2009, Pages: 126
Urinary tract infections (UTIs) include infections of the kidneys, ureters, and bladder. Escherichia coli is the major UTI pathogen, with emerging extended-spectrum beta-lactamase (ESBL)-producing strains proving particularly difficult to treat. Bacterial resistance to the most commonly used UTI drugs is growing, highlighting the unmet need and opportunity for novel therapies.
Scope
- Disease background, segmentation and epidemiology of UTIs in the US, Japan and five major European countries
- Overview of unmet needs, current clinical practice, guidelines and adherence
- Discussion of trends in incidence of major pathogens and therapies as well as resistance rates
- Outline of diagnosis, treatment and referral patterns
Highlights of this title
UTIs are a major driver of ambulatory care utilization. US statistics point to more than 10 million visits to ambulatory care settings for UTIs per year. From 1995 to 2006, the incidence of cystitis and UTI in unspecified sites in the US increased by 10.7%.
Bacterial resistance is the most important factor affecting UTI treatment options and varies both nationally and locally. Resistance rates as low as 10% are deemed to be of concern with regards to efficacy of empiric therapy. Levels of resistance to some older drugs may reach 40-50% in some areas, rendering these drugs ineffective.
Two old drugs, nitrofurantoin and fosfomycin, have remarkably favorable resistance profiles and good efficacy for the treatment of cystitis, and therefore may provide highly useful future treatment options. Given these compounds age, they are not widely prescribed, requiring physician education to improve familiarity and improve their uptake.
Key reasons to purchase this title
- Learn about the significance of UTIs as a an indication for antibacterial compounds
- Understand and capitalize on clinical unmet needs in the market through new product development in therapy and diagnosis
- Discover optimal ways to communicate with physicians by supporting efforts to address gaps in diagnosis, treatment and guideline adherence
|
|
|
|
